Biosig Technologies Inc

NASDAQ:BSGM  
3.32
+0.13 (+4.08%)
Products, Expansion, Regulatory

Viralclear Expands Ongoing Phase 2 Trial Size For Its Oral Anti-Viral For Treatment Of Covid-19

Published: 09/22/2020 16:01 GMT
Biosig Technologies Inc (BSGM) - Viralclear Expands Ongoing Phase 2 Trial Size for Its Oral Anti-viral for the Treatment of Covid-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution.
Biosig Technologies Inc - Size of Ongoing Phase 2 Trial of Merimepodib in Combination With Remdesivir Increased From 40 to 80 Subjects.
Biosig Technologies Inc - Added 2 New Principal Investigators for Ongoing Phase 2 Trial Expanding Total Number of Locations to 10.
Biosig Technologies Inc - Cmo Appointed to Manufacture Phase 3 Supplies of Merimepodib Oral Solution.
Biosig Technologies Inc - Merimepodib Monotherapy Trial to Be Conducted in Outpatient Setting After Current Combination Trial Completes.
Biosig Technologies- Once Additional Subjects Are Enrolled, Further Clinical Data is Got, Team to Discuss With FDA Appropriate Size for Phase 3 Trial.